To develop a safe and effective respiratory syncytial virus (RSV) vaccine for use in early life, Boston Children's Hospital scientists and their collaborators developed CAF-08, a liposomal formulation consisting of combined TLR7 (3M-052) and Mincle (trehalose-6,6-dibehenate [TDB]) agonists and the RSV pre-F antigen.